

User Guide 使用說明

<u>日 次</u>

一、臨床問題	P.1
二、主畫面說明	P.2
三、New Search	P.4
四、Topic Review 全文資料顯示	P.5
五、檢索結果輸出	P.8
六、Lexi-Comp 藥物交互作用	P.9
七、Evidence Grading 證據等級	P.11
八、Patient Information 衛教資料	P.12
九、Calculators 試算表	P.13
十、ECG Test 心電圖自我測驗	P.14

95 Sawyer Road · Waltham, MA 02453-3471 USA Phone: (800) 998-6374 · (781) 392-2000 Fax: Sales (781) 642-8840 · Editorial (781) 642-8867 www.uptodate.com





How effective is long-term warfarin at preventing recurrent pulmonary embolism ?

長期使用 Warfarin 在預防肺栓塞的復發有多大的效果?

二、 主畫面說明

進入 UpToDate 即進入 UpToDate 的主畫面,如(圖一)所示:

	(8)
Very Search Patient Info What's New Calculators	About Us : News from UpToDate : Contact Us : Help
(1) (3)	
New Search: (5) Al Topics V Seiarch Drug Interactions (7)	
Ø 2013 UpToDate, Inc. All rights reserved. Subscription and License Agreement Release: 21.2 - C21.17 Licensed to: Uptodate Support Tag: [1104-10.25.60.80-834E338C8D-1979.14]	
	(圖一)

◎以下之說明對應於(圖一)所標示之號碼

- (1) New Search:檢索畫面,亦為回到主畫面之選項
- (2) Patient Information: UpToDate 提供了超過 1000+ Patient information

亦可於檢索區輸入欲查詢之 Patient information

例如: patient info hypertension

- (3) What's New:每次新版更新時,主編們會摘選最重要的資料並以最簡要的方式呈現
- (4) Calculators: 目前提供 135 種試算表
- (5) New Search:指令欄/檢索區,可輸入單一關鍵字、詞句或問題
- (6) Search:執行檢索
- (7) Drug Interactions: Lexi-Comp 藥物交互作用模組

(8) 其他選項

News from UpToDate: UpToDate 的新訊以及新知

Contact us: UpToDate 聯絡資料

About UpToDate: UpToDate 內容說明

Help:線上求助

- ◎ <u>New Search</u>指令欄/檢索區說明:
 - (1) 可輸入:病名(diseases)、症狀(symptoms)、程序(procedures)、藥名(drugs)、 實驗室異常(laboratory abnormalities)
 - (2) UpToDate 可辨識同義字(synonyms)、縮寫(abbreviations or acronyms)以及字根 (word roots)
 - (3) UpToDate 會自動做拼字檢查
 - (4) 可加入適當的關鍵字,以縮小檢索結果在特定的年齡層,例如: in adults, in children 或 in pregnancy
 - (5) Gracph searcah 圖片檢索:亦可以直接搜索 UpToDate 裡的圖片

三、 New Search:開始檢索

(1) New Search: 輸入關鍵字

- a. 可直接輸入單一關鍵字、多個關鍵字、詞句或問題,如(圖二)所示。
 例如:『treatment of hypertension in pregnancy』、
 『warfarin and PE』(以臨床問題為例之檢索詞)
- b. 檢索結果,如(圖三)所示。

上方:指令欄

- 左方:檢索結果:
 - 依關鍵字的相關性依序列出檢索結果;
 - 亦可改變檢索結果的排列順序,將其有相關的文章排列於前,分別有 All Topics、Adult、Pediatrics、Patient 以及 Graphics,這五種選 擇,如(圖三)所示;
 - 一頁以 50 筆的檢索結果為上限,若超過 50 筆,頁碼列於檢索結果最下方,如(圖四)所示;
- 右方:Topic Outline,將滑鼠移至左方之檢索結果 Topic 的上方(不需要點選),右 方即會出現該篇 Outline 以供瀏覽

UpToDate.			Ab	out Us News from UpToDate	Contact Us Help
×	t Info What's New Calculators				▶ Log in
@ 2013 UpToDate. Inc. A	Info What's New Calculators New Seat	e All Topics - Search			+ Log in
					(圖二)
UpToDate.	warfarin and pe All Topics V Search		Ab	out Us News from UpToDate	Contact Us Help
×	t Info What's New Calculators				▶ Log in
Search Results for "w					
pe means pulmonary	embolism. Click alternative term: etoposide cisplatin		Topic Outline		
Click related term for	warfarin: antithrombotic therapy				
All Topics Adult Pediatric	Anticoagulation in acute pulmonary embolism • Ireatment of acute pulmonary embolism		INTRODUCTION INITIATION OF ANTICOAGULANT LOW MOLECULAR WEIGHT HER		
O Patient	Management of anticoagulation before and after elective surgery Anticoagulation in older adults		 Evidence Dosing 		=
O Graphics 💽	Anticoaguiation in older adults Low molecular weight heparin for venous thromboembolic disease		Monitoring	LIN .	
	Prevention of venous thromboembolic disease in medical patients		 SUBCUTANEOUS FONDAPARIN Evidence 	UX	
	Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention		Dosing		
	Treatment of the antiphospholipid syndrome		Monitoring		

	Monitoring	
 Treatment of the antiphospholipid syndrome 	UNFRACTIONATED HEPARIN	
 Indications for antithrombotic therapy in heart failure 	Indications	
Correcting excess anticoagulation after warfarin	Dosing	
 Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children 	- Intravenous	
5	- Subcutaneous	
Warfarin: Pediatric drug information	Monitoring	
 Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment 	WARFARIN	
 Anticoagulant and antiplatelet therapy in patients with brain tumors 	Initiation	
	• Dosing	
 Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage 	Monitoring	
Renal vein thromhosis and hypercoardable state in nenhratic syndrome	- DABIGATRAN	•
 2059 (contents/anticongulation in acute nulmonany ambalism?course coarch result9:coarch a	Internet Protected Media Off	

UpToDate.	warfarin and pe All Topics 👻 Search	About Us News from UpToDate Contact Us Hel
New Search Patier	nt Info What's New Calculators) Log i
Search Results for "w	/arfarin and pe"	
e means <i>pulmonary</i>	embolism. Click alternative term: etoposide cisplatin	Topic Outline
lick related term for	warfarin: antithrombotic therapy	
All Topics	 тре аполновой спетару играненсь мин сагоочассная споказе 	 INTRODUCTION
O Adult	 Evaluation of the patient with established venous thrombosis 	EPIDEMIOLOGY
Pediatric	 Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues 	 Risk factors
	Therapeutic use of fondaparinux	Renal vein thrombosis
 Patient 	Anticoagulants other than heparin and warfarin	Deep vein thrombosis Pulmonary embolism
 Graphics 	Treatment of idiopathic pulmonary fibrosis	PATHOGENESIS
	Management of thrombosis in the newborn	RENAL VEIN THROMBOSIS
	Therapeutic uses of recombinant coagulation factor VIIa	Clinical features
	 Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults 	- Chronic renal vein thrombosis
		Acute renal vein thrombosis Diagnosis and screening
	 Endovenous laser ablation for the treatment of lower extremity chronic venous disease 	TREATMENT
	Evaluation of infection in the older adult	Prevention of thromboembolism
	Protein S deficiency	Prophylactic anticoagulation
	Management of inherited thrombophilia	- Anticoagulation for asymptomatic RVT
	Hypercoagulable disorders associated with mangnancy	- Anticoagulation for a thromboembolic event
	- Hypercodynable disorders associated with hunghaney	Duration of anticoagulation
	123	Inferior vena cava filters Direct therapy of RVT
	Il rights reserved. Subscription and License Agreement Release: 21.2 - C21.17 Support Tag: [1104-10.25.50.80-834E33BC60-1979.14]	- Fibrinolytic therapy and catheter thrombectomy

- 四、 Topic review:全文資料
 - (1) Outline 目次:於畫面左方,可利用目次先尋找關鍵字,可發現問題答案所在,直接點選會連接至該段落,並增加 SUMMARY & RECOMMENDATINOS 快速鍵.
 - (2) Author/Section Editor/Deputy Editor 作者及編輯群:提供這篇 Topic review 所

有參與的作者與編輯者資

訊,如(圖六)所示

- (3) Date 更新日期:列出本文最新被更新的日期,如(圖六)所示
- (4) Reference 參考書目:如(圖七)所示;
 - a.本文中有參考書目之序號,點選序號,會另開視窗,顯示出 Medline Abstracts
 b.可點選 Outline 處之 Reference,即列出所有本文之參考書目清單,亦列於本文 末處,以綠色顯示之參考書目可帶出 Medline Abstracts
- (5) Graphics 圖表:如(圖八)、(圖九)所示
 - a.點選圖表,則另開一視窗,顯示其圖表
 - b.圖表可另外下載,利用 email、print、Export to Powerpoint 或輸出工具列 (滑鼠移至圖表上即會出現)
- (6) Drug Information 藥物資訊:藥物品名以綠色字呈現,點選後會另開啟一視窗, 此為 Lexi-comp 藥學資訊的詳細介紹
- (7) Related Topics 相關文獻:提供除本文外,與 UpToDate 裡相關主題的 Topic review,直接點選可直接進入該篇 Related Topic 的 全文資料
- (8) Find in Topic 查找關鍵字:可利用此功能查詢出文章裡的關鍵字,如(圖十)、 (圖十一)所示
- (9) Patient Info 衛教資料:若此文章有 Patient Information,點選此功能會直接顯示 Information for patients 此段落之內容

UpToDate. warfarin and pe	All Topics - Search		About Us 🕕 News from	m UpToDate Contact Us Help 🖌
New Search Patient Info What's New	/ Calculators			▶ Log in
		S Back to Search Results		
Anticoagulation in acute pulmonary emb	olism		(2) Find (Patient 🔒 Print 🖾 Email
	Anticoagulation in acute pulmonary embolism	(2)		
SUMMARY & RECOMMENDATIONS A INTRODUCTION INITATION OF ANTICOAGUL THERAPY	Authors Se	ection Editor sss Mandel, MD	Deputy Editor Geraldine Finlay, MD	
LOW MOLECULAR WEIGHT HEPARIN Evidence Dosing Monitoring	All topics are updated as new evidence becomes available and Literature review current through: Jan 2013. This topic la INTRODUCTION — Anticoaculation is the main therapy for acc	st updated: Nov 12, 2012.	o decrease modality by prevention (3) In the or	nly trial ever performed
SUBCUTANEOUS FONDAPARINUX • Evidence • Dosing	that compared treatment with anticoagulants to no treatment, a mortality [2-4].	anticoagulation decreased mortality [1]. Su		
Monitoring UNFRACTIONATED HEPARIN Indications Dosing	Common questions asked by clinicians caring for patients with Should I initiate anticoagulant therapy? Which anticoagulant should I initiate? What is the appropriate dose?	acute PE include the following:		Topic Feedb
- Intravenous - Subcutaneous • Monitoring WARFARIN Initiation	 How should I monitor the treatment? What is the clinical evidence supporting its use? What are the common complications? For how long should I treat? 			
Initiation Dosing Monitoring DABIGATRAN	Each of these issues is reviewed here. Other aspects of the tre "Treatment of acute pulmonary embolism" and "Fibrinolytic (thr vena cava filters and their complications".)			
			Internet Protected Mode: Off	🔩 🕶 🔍 100% 💌
				(圖六)









(圖九)

	alculators			→ Log in
		S Back to Search Results		
Anticoagulation in acute pulmonary embolism	i		(8) 🗅 🕫	nd 🔞 Patient 🖨 Print 🖾 Email
TOPIC OUTLINE				
SUMMARY & RECOMMENDATIONS A	Anticoagulation in acute pulmonary embo	lism		(9)
	Authors Karen A Valentine, MD, PhD Russell D Hull, MBBS, MSc	Section Editor Jess Mandel, MD	Deputy Editor Geraldine Finlay, MD	
THERAPY	Disclosures			
Evidence Dosing	All topics are updated as new evidence becom Literature review current through: Jan 2013	es available and our <u>peer review process</u> is complete. 3. This topic last updated: Nov 12, 2012.		
Monitoring SUBCUTANEOUS FONDAPARINUX Evidence			I is to decrease mortality by preventing recurrent PE. In the]. Subsequent uncontrolled trials have confirmed that antice	coagulation decreases
Dosing Monitoring	Common questions asked by clinicians caring	for patients with acute PE include the following:		edbae
Indications	 Should I initiate anticoagulant therapy? Which anticoagulant should I initiate? What is the appropriate dose? 			Topic Feedback
	 How should I monitor the treatment? What is the clinical widence supportion 	te usa?		
Dosing Intravenous	 How should I monitor the treatment? What is the clinical evidence supporting What are the common complications? For how long should I treat? 	its use?		

New Search Patient Info What's New Ca	alculators			► Log
		S Back to Search Results		
Anticoagulation in acute pulmonary embolism				🕼 Find 🔞 Patient 🖨 Print 🖾 Ems
				Find in Topic 🗙
SUMMARY & RECOMMENDATIONS	Anticoagulation in acute pulmonary emb	olism		We found 132 instances of "warfarin and pe"
INTRODUCTION	Authors Karen A Valentine, MD, PhD Russell D Hull, MBBS, MSc	Section Editor Jess Mandel, MD	Deputy Editor Geraldine Finlay, MD	1 of 132 highlighted Next Clear
THERAPY	Disclosures			
Evidence Dosing	All topics are updated as new evidence become Literature review current through: Jan 20	mes available and our <u>peer review process</u> is complete. 13. This topic last updated: Nov 12, 2012.		
Monitoring SUBCUTANEOUS FONDAPARINUX Evidence		ain therapy for acute pulmonary embolism (PE). Its goat to no treatment, anticoagulation decreased mortality [
Dosing Monitoring		g for patients with acute PE include the following:		
UNFRACTIONATED HEPARIN Indications	 Should I initiate anticoagulant therapy 	?		
Indications Dosing	 Which anticoagulant should l initiate? What is the appropriate dose? 			
- Intravenous	How should I monitor the treatment?			
- Subcutaneous	 What is the clinical evidence supporting 	no its use?		
Monitoring	 What are the common complications? 			
WARFARIN	For how long should I treat?			
Initiation	5			
Dosing		aspects of the treatment of acute PE, including thromi		
Monitoring		d <u>"Fibrinolytic (thrombolytic) therapy in acute pulmona</u>	ry embolism and lower extremity deep vein thro	mbosis" and "Placement of inferior
DABIGATRAN +	vena cava filters and their complications".)			
Done			Internet Protected Mode: O	ff 🛛 👫 🔻 🔍 100%

- 五、 檢索結果輸出:如(圖十二)、(圖十三)所示。
 - (1) Print : 調整 Topic review 呈現畫面,會將所有圖表放置於文章之後,再執行印 表機功能。
 - (2) Email: email Topic review,只傳送文字部份。

UpToDate. warfarin and pe	All Topics 👻 Search		About Us 👔 News fro	om UpToDate Contact Us Help 🔺
New Search Patient Info What's New Cal	culators			► Log in
		S Back to Search Results		
Anticoagulation in acute pulmonary embolism			A Find	😰 Patient 🖨 Print 🖾 Email
TOPIC OUTLINE				
SUMMARY & RECOMMENDATIONS	Anticoagulation in acute pulmonary embolism			
INTRODUCTION	Authors Karen A Valentine, MD, PhD Russell D Hull, MBBS, MSc Disclosures	Section Editor Jess Mandel, MD	Deputy Editor Geraldine Finlay, MD	
LOW MOLECULAR WEIGHT HEPARIN Evidence Dosing	All topics are updated as new evidence becomes available a Literature review current through: Jan 2013. This topic		te.	
Monitoring SUBCUTANEOUS FONDAPARINUX Evidence			goal is to decrease mortality by preventing recurrent PE. In the or [1]. Subsequent uncontrolled trials have confirmed that anticoa	
Dosing Monitoring UNFRACTIONATED HEPARIN	Common questions asked by clinicians caring for patients v	with acute PE include the following:		eedbac
Indications Dosing	 Should I initiate anticoagulant therapy? Which anticoagulant should I initiate? What is the appropriate dose? 			Topic
- Intravenous - Subcutaneous	 What is the appropriate dose? How should I monitor the treatment? What is the clinical evidence supporting its use? 			
Monitoring WARFARIN	 What is the clinical evidence supporting its use? What are the common complications? For how long should I treat? 			
InitiationDosing	Each of these issues is reviewed here. Other aspects of the		mbolysis, inferior vena caval filters, and embolectomy are discu	
Monitoring DABIGATRAN	"Treatment of acute pulmonary embolism" and "Fibrinolytic vena cava filters and their complications".)	(thrombolytic) therapy in acute pulmo	nary embolism and lower extremity deep vein thrombosis" and "	Placement of inferior
Done			Internet Protected Mode: Off	🔩 🔻 🍕 100% 💌 🖉
				(圖十二)



六、 Drug Interactions: Lexi-Comp 藥物交互作用

可以輸入二種以上的藥品,包含 drug-to-drug、herb-to-herb、drug-to-herb,執行 並產生交互作用的結果,且有標示交互作用的等級。

(1)在主畫面的下方,直接點選:

UpToDate. New Search Patient Info What's New Calculators	About l	Us : News from UpToDate : Contact Us : Help ▶ Log in
New Search Patient into What's New Calculators	New Search: Drug Interactions	, Lôg m
E 2013 Up ToDate, Inc. All rights reserved. Subscription and License Agreement Licenses to: Uptodate Support Tag: [1104-10.25.50.80-634E33804D-1873.14] Done	Refease: 21.2 - C21.17	
		(圖十四)

(2)翰入二種欲查詢之藥品,執行「Analyze」:

Lexicomp [®] Lexi- Interact™	Welcome to Lexi-Interact™ Online
Lookup Enter item name to lookup.	Lexi-Comp's Comprehensive Drug-to-Drug, Drug-to-Herb and Herb-to-Herb Interaction Analysis Program
Analyze New List	NOTE: Lexi-Interact does not address chemical compatibility related to I.V. drug preparation or administration.
 ✓ Aspirin ✓ Warfarin 	Lexi-Interact Online combines the world's literature and scientific understanding of drug interactions with a state-of-the-art electronic platform, providing an efficient way to ensure that adverse drug events don't compromise the care of your patients.
Display complete list of interactions for an individual item by clicking item name. Add another item(s) [Lookup] to Analyze for potential interactions between items in the list.	Review all interactions for a selected medication or enter a patient specific regimen to analyze for potential interactions. Additionally, you may select a drug interaction result to obtain detailed information on Patient Management, Interacting Members, Risk Rating, References and more.
Remove terms in the list by clicking the check mark next to the item name.	Disclaimer While great care has been taken to ensure the accuracy of the information presented, the user is advised that the authors, editors, reviewers, contributors, and publishers cannot be responsible for the continued currency of the information or for any errors, omissions, or the application of this information, or for any consequences arising therefrom. Therefore, the author(s) and/or the publisher shall have no liability to any person or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly, by the use of information contained herein. Because of the dynamic nature of drug information, readers are advised that decisions regarding drug therapy must be based on the independent judgment of the clinician, changing information about a drug (eg, as reflected in the literature and manufacturer's most current product information), and changing medical practices. The editors are not responsible for any inaccuracy of quotation or for any false or misleading implication that may arise due to the text or formulas as used or due to the quotation of revisions no longer official.
J	😜 Internet Protected Mode: Off

(圖十五)

(3)右邊畫面會出現結果,『risk rating』為交互作用的等級說明:

Lexicomp [®] Lexi- Interact™	Lexi-Comp Online [™] Interaction Analysis
Lookup Enter item name to lookup. Analyze NewList Same Same Same Same Same Same Same Same	Customize Analysis Only interactions at or above the selected risk rating will be displayed. A View interaction detail by clicking on link: Aspirin [D] Warfarin (Vitamin K Antagonists) Warfarin [D] Aspirin (Salicylates) Date March 3, 2013 Disclaimer Readers are advised that decisions regarding drug therapy must be based on the independent judgment of the clinician, changing information about a drug (eg, as reflected in the literature and manufacturer's most current product information), and changing medical practices. Lexicomp® Copyright © 1978-2013 Lexi-Comp Inc. All Rights Reserved
	🕥 Internet Protected Mode: Off 🛛 🕀 👻 🎕 100% 💌 🚽
	(圖十六)

(4)『Risk Rating』說明如下:
 Risk Rating 分成五個等級,分別是:A、B、C、D、X。

Lexicomp [®] Lexi- Interact™ Enter item name to lookup.	Risk Rating: Rapid indicator regarding how to respond to the interaction data. Each Interact monograph is assigned a risk rating of A, B, C, D, or X. The progression from A to X is accompanied by increased urgency for responding to the data. In general, A and B monographs are of academic, but not clinical concern. Monographs rated C, D, or X always require the user's attention. The text of the Patient Management section of the monographs will provide assistance regarding the types of actions that could be taken. The definition of each risk rating is as follows:					^
Analyze New List		Risk Rating	Action	Description		Ξ
Warfarin Warfarin Warfarin Warbard Complete list of interactions for an individual item by clicking item name. Add another item(s) [Lookup] to Analyze for yotential interactions between items in the list. Remove item from the list by clicking the check mark next to the item name.	A B C	Α	No Known Interaction	Data have not demonstrated either pharmacodynamic or pharmacokinetic interactions between the specified agents		
		В	No Action Needed	Data demonstrate that the specified agents may interact with each other, but there is little to no evidence of clinical concern resulting from their concomitant use.		
		C	Monitor Therapy	Data demonstrate that the specified agents may interact with each other in a clinically significant manner. The benefits of concomitant use of these two medications usually outweigh the risks. An appropriate monitoring plan should be implemented to identify potential perative effect. Desage		Ŧ
Done				Internet Protected Mode: Off	🔩 🕶 🔍 100% 🔻	•
					1	````````````````````````````````````

(圖十七)

七、 Evidence Grading: 證據等級

位於 Topic review 目次中的 <u>Recommendations</u> 的這個段落裡:如(圖十八)所示。

UpToDate.	warfarin and pe	All Topics 👻 Search		About Us I News from UpToDate	Contact Us H	Help 🔺
New Search Patient	Info What's New Cale	culators) ► Lo	g in
			Back to Search Results			_
Anticoagulation in acut	e pulmonary embolism			🕼 Find 😰 Patient	🕒 Print 🖾 Em	hail
Recurrent PE	*	SUMMARY AND RECOMMENDATIONS				
 Secondary prevention thromboembolism 	of venous	Initial therapy				
SPECIAL CONSIDERA Cancer Pregnancy	TIONS	 We recommend parenteral anticoagulation in patients with anticoagulant therapy' above.) 	confirmed acute pulmonary embolism (PE), rather than no anticoagulation	(<u>algorithm 1)</u> (<mark>Grade 1A</mark>). (See)	Initiation of	
INFORMATION FOR PA SUMMARY AND RECOMMENDATIONS	ATIENTS		rmed (<u>algorithm 1</u>) (see <u>Initiation of anticoagulant therapy</u> above): : is a high clinical suspicion of acute PE, rather than no anticoagulation (G	rade 1B).		
 Initial therapy Long-term therapy Duration 		hours, rather than no anticoagulation (Grade 2C).	a moderate clinical suspicion for acute PE and the results of the diagnostic			
REFERENCES	=	 We suggest parenteral anticongulation when there is rather than no anticoagulation (<u>Grade 2C</u>). 	a low clinical suspicion for acute PE and the results of the diagnostic tests	are expected to take longer than	24 hours,	ž
GRAPHICS 💽 View All			using a validated prediction rule, such as the Wells criteria (<u>table 1</u>) (<u>calcul</u>	<u>ator 1)</u> .		ledba
 ALGORITHMS PE treatment algorith 	-	 Anticoagulant therapy should be continued during the 	diagnostic evaluation.			ic Fe
TABLES		 The following recommendations assume that the decision 	has been made to initiate parenteral anticoagulant therapy:			Ę
 Wells criteria and mo criteria Weight based heparin Heparin protocol I 		intravenous unfractionated heparin (IV UFI) (Grade 1	n suspected acute PE, we recommend initial treatment with low molecular B). We also suggest LMWH rather than subcutaneous <u>fondaparinus</u> (<u>Grad</u> e 2B). (\$ se <u>"initiation of anticoagulant therapy</u> above.)			
Heparin protocol II CALCULATORS Calculator: Pulmonary e	and a linear MALIA		no have dersistent hypotension due to the acute PE, an increased risk of bl rsis may be performed, we suggest IV UFH rather than an alternative antico			
Score	The second secon	For patients with confirmed or suspected acute PE a	ld severe renal failure (creatinine clearance ≤30 mL/min). we succest UFH	rather than LMWH or subcutaned	us	Ψ.
			Internet Protected Mo	ode: Off 🗧 🗧	🔹 🔍 100%	•
				(圖十八	、)

亦可點選 Evidence Grading,如上圖所示之 (Grade 1A),會跳出說明視窗,如(圖十九) 所示。

UpToDate.				
e2013 UpToDate®	Print			
Grade 1A recommendation				
A Grade 1A recommendation is a strong recommendation, and applies to most patients in most circumstances without reservation. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.				
Explanation:	1			
A Grade 1 recommendation is a strong recommendation. It means that we believe that if you follow the recommendation, you will be doing more good than harm for most, if not all of your patients.	1			
Grade A means that the best estimates of the critical benefits and risks come from consistent data from well-performed, randomized, controlled trials or overwhelming data of some other form (eg, well-executed observational studies with very large treatment effects). Further research is unlikely to have an impact on our confidence in the estimates of benefit and risk.				
Recommendation grades 1. Strong recommendation: Benefits dearly outweigh the risks and burdens (or vice versa) for most, if not all, patients 2. Weak recommendation: Benefits and risks closely balanced and/or uncertain Evidence grades A. High-quality evidence: Consistent evidence from randomized trials, or overwhelming evidence of some other form B. Moderate-quality evidence: Evidence from randomized trials, or overwhelming evidence of some other form C. Low-quality evidence: Evidence from observational studies, unsystematic clinical observations, or from randomized trials with serious flaws For a complete description of our grading system, please see the UpToDate editorial policy which can be found at www.uptodate.com/home/editorial-policy.				
Done 🕒 🖓 🖓 Done Done Done Done Done Done Done Done	· •			
(圖十九	L)			

註:目前並未全部都有 Evidence Grading

八、 Patient Information 衛教資料

Patient Information 提供二種版本

- The Basics: 以一至三頁為主,回答四到五個最重要的問題,並使用較多的圖表來呈現。
- Beyond the Basics:五至十頁,為比"The Bascis"版本較詳細的內容,並使用一些醫學專有名詞來解釋。



九、 Calculators : 試算表

UpToDate 目前提供了 135 種的試算表,直接點選 Calculators 的頁面選項,會先列 出科別,進一步點選後,會再列出相關的試算表,如(圖二十)所示:

UpToDate.	All Topics 👻 Search		About Us News from Up	ToDate Contact Us Help			
New Search Patient Info What's New C	Calculators			▶ Log in			
Contents > Calculators				e Print			
Specialties							
Patient Information	Contents: Calculators						
What's New Calculators	You receive the entire UpToDate library of specialties with your subscription. Click on a section below to view a detailed list of topics associated with that particular section. If you'd like to see the ta of contents for other specialties, click here.						
Authors and Editors	Cardiology calculators Critical care calculators Emergency med calculators Endocrinology calculators Gastroenterology and Hepatology calculators General surgery calculators Patient Information	Hematology calculators Hospital medicine calculators ID calculators Nephrology calculators Neurology calculators Obstetrics calculators	Oncology calculators Pediatrics calculators Primary care calculators Pulmonology calculators Rheumatology calculators				
	© 2013 UpToDate, Inc. All rights reserved. Subscription an Licensed to: Uptodate Support Tag (1104-10.25.80.30-834	E33BC6D-1979.14]		√ ♥ ♥ 100% ▼			
Done		•	Internet Protected Mode: Off	√2			
				圖二十一)			

十、 ECG Test : 心電圖自我測驗

UpToDate 目前提供了 3 級的自我測試,分別為初級、中級、高級,只需要在檢索區 裡鍵入 ECG Test,檢索結果裡第一筆(Basic ECG test)、第二筆(Intermediate ECG test)和第三筆(Advanced ECG test)即為心電圖自我測試,如(圖二十二) 所示:

